LogFAQs > #962725718

COVxy posted...

This is my biggest pet peeve. Sample size was small in comparison to what? Why do you think the sample size was too small?

I mean, they managed to get their hands on 171 samples of pre-Covid blood. Having a larger and broader sample size would have helped illustrate, for example, how the length of time beyond vaccination or infection impacts the presence of the RBD antibody. According to the clinical trial page they reference there were 236 total participants, but for the experiment they only use 28 samples from vaccinated subjects and 41 samples from 33 previously infected subjects. Im curious as to what criteria they used to select these samples. Notably, none of the convalescent samples were from subjects who had experienced Covid symptoms less than 100 days prior to donation, and conversely only 3 of the samples from vaccinated subjects were from patients who had been vaccinated more than 100 days prior to participation. The third cohort of 39 samples didnt come from the same trial and are from patients we dont have any information about at all. There is lots of room for unseen variables because of the sample populations chosen, imo, and having larger and broader sample sizes would provide more useful data than just people vaccinated a median of 35 days ago have significantly more protection against Covid than people who naturally had the virus a median of 201 days ago.